Detail akcie Oxford Biomedica Rg online

Business Summary: Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. The Company is engaged in providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers a number of technologies for viral vector manufacturing, including a fourth-generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. Its AAV platform, which offers a proprietary plug and play dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Oxford BioMedica plc revenues increased 44% to L73.2M. Net loss decreased 19% to L26.4M. Revenues reflect United States of America segment increase of 82% to L58.2M. Lower net loss reflects Innovation costs decrease of 87% to L2M (expense), Other Non Operating I/E increase from L358K (expense) to L3.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -L0.31 to -L0.25.